• Eight Rheumatic Diseases With One Blood Draw

    Information provided by Quest Diagnostics

    Female doctor and patient on medical exam.

    ANA IFA Cascade with IdentRA panel combines sensitivity and specificity of various markers to aid in differential diagnosis for the eight most common rheumatic diseases:

    •  Systemic Lupus Erythematosus (SLE)
    • Mixed Connective Tissue Disease
    • Systemic Sclerosis
    •  Rheumatoid Arthritis (RA)
    • Sjögren’s Syndrome
    • Polymyositis
    • CREST Syndrome
    • Neuropsychiatric SLE

    ANA IFA Cascade with IdentRA:

    • Screens antinuclear autoantibodies (ANA) using the gold standard, highly sensitive immunofluorescence assay (IFA) with HEp-2 cells
    • Automatically reflexes a positive ANA screen to a tiered cascade of specific antibodies for a complete result
    • IdentRA® panel components include:
      • Widely used RA markers RF (rheumatoid factor) and CCP (cyclic citrullinated peptide)
      • Serum 14-3-3η (eta) protein, a marker for RA that improves identification of early and established RA1,2,3 in addition to providing prognostic information4,5

    Quest now offers special VIP-level access to our patient service centers for your vulnerable, immunocompromised patients. Our Peace of Mind program and the ANA IFA Cascade with IdentRA panel enable them to get the non-COVID-19 lab testing they need in a clean environment that’s designed to minimize patient interactions. Using Quest Diagnostics as an extension of your practice gives you more than quality results. Our program helps to optimize patient care with improved compliance when in-office testing isn’t an option.

     

    1.  Jansen AL, van der Horst-Bruinsma I, van Schaardenburg D, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 2002;29:2074-2076.
    2.  Maksymowych WP, Naides SJ, Bykerk V, et al. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104-2113.
    3. Naides SJ, Marotta A. 14-3-3η in “seronegative” rheumatoid arthritis. J Rheumatol. 2015;42(10):1995.
    4. Carrier N, Marotta A, de Brum-Fernandes AJ, et al. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 2016;18:37.
    5. van Beers-Tas MH, Marotta A, Boers M, et al. A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgia. Arthritis Res Ther. 2016;18:76.

    About Sponsored Content

    The posting of sponsored information and content on this page should not be considered an AAFP endorsement or recommendation of the sponsor's products, services, policies, or procedures. The information and opinions expressed on this page are those of the paid sponsors and do not necessarily reflect the view of the AAFP. The AAFP is not responsible for the content of third-party websites linked from this page; moreover, any links on this page to third-party websites where goods or services are advertised are not endorsements or recommendations by the AAFP of the third-party sites, goods, or services.